Trace Levels of Innate Immune Response Modulating Impurities (IIRMIs) Synergize to Break Tolerance to Therapeutic Proteins-Reference-Cited by-同舟云学术

Trace Levels of Innate Immune Response Modulating Impurities (IIRMIs) Synergize to Break Tolerance to Therapeutic Proteins

Published:2010-12-22 Issue:12 Volume:5 Page:e15252
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Verthelyi Daniela,Wang Vivian

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference55 articles.

1. A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 1: Considering Consequences of the Immune Response to a Protein.;A Worobec;Bio Pharm Int,2005

2. How to predict and prevent the immunogenicity of therapeutic proteins.;H Schellekens,2008

3. Immunogenicity of biological therapeutics: a hierarchy of concerns.;AS Rosenberg;Dev Biol (Basel),2003

4. Immunogenicity of therapeutic proteins: Clinical implications and future prospects.;H Schellekens;Clin Therapeutics,2002

5. Immunogenicity of recombinant human proteins: causes and consequences.;H Schellekens;J Neurol,2004

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Eye;Haschek and Rousseaux' s Handbook of Toxicologic Pathology;2024

2. Safety Evaluation of Ocular Drugs;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

3. Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics;Life Science Alliance;2023-10-13

4. Immunogenicity risk assessment of synthetic peptide drugs and their impurities;Drug Discovery Today;2023-10

5. Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives;Journal of Pharmaceutical and Biomedical Analysis;2023-09